Is Pier 1 Imports A Good Stock To Buy On The Cheap? This Consumer Stocks Expert Thinks So

At the end of the first quarter, Glenhill Advisors’ had bought 5.28 million shares of Pier 1 Imports, Inc. (NYSE:PIR) valued at $73.76 million, a new position for the fund. Credit Suisse analyst Seth Sigman is maintaining a cautious approach with respect to the prospects of the Home Furnishing Segment in which Pier 1 Imports Inc (NYSE:PIR) is a key player. Increased investments in e-commerce, as well as promotional activity, continues to drag margins in the sector, something that the analyst fears could affect returns this year. Nonetheless, Pier 1 Imports Inc (NYSE:PIR) has the highest gains in the sector this year, but has still left a lot to be desired as demand in the sector remains low compared to previous highs. The company is, however showing signs of improvement as it has seemingly moved past supply chain issues that dragged it down in 2014. Mario Gabelli‘s GAMCO Investors reported holding 1.38 million shares of Pier 1 with a value is $19.32 million as of March 31.

Glenhill Advisors owned 5.82 million shares of Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) with a market value of $69.61 million on March 31, a big increase from the 3.03 million shares it held at the end of 2014. East Kent Hospitals University NHS Foundation Trust, and Maidstone and Tunbridge Wells NHS Trust are the latest partners to deploy Allscripts Healthcare Solutions Inc (NASDAQ:MDRX)’s PAS to replace their existing systems. The two organizations are set to enjoy access to highly flexible and configurable solutions for managing their patients’ data. East Kent Hospitals and Maidstone and Tunbridge join more than a dozen Trusts and hospitals already using Allscripts PAS. Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) is renowned for being highly reliable in delivering value-added client care while enabling hospitals and Trusts to deliver excellent care for patients. The two agreements highlight Allscripts Healthcare Solutions Inc (NASDAQ:MDRX)’s desire to expand its presence in the UK, having been awarded the NHS SBS Clinical Information Systems Framework. Out of the 730 actively reporting hedge funds that we tracked during the first quarter, 28 of them had stakes in the company at the end of the quarter, with their total investment valued at $471.33 million. A few of the funds that had stakes in the stock are Clifton S. Robbins’ Blue Harbour Group, Ken Griffin’s Citadel Investment Group, and Jacob Gottlieb’s Visium Asset Management.

Disclosure: None